Imbria Pharmaceuticals Completes Enrollment in the Phase 2 IMPROVE-ISCHEMIA Clinical Trial of Ninerafaxstat in Patients with Stable Angina
16 août 2023 08h00 HE
|
Imbria Pharmaceuticals Inc.
– IMPROVE-ISCHEMIA, a randomized, placebo-controlled trial, with topline data expected in 4Q 2023 – – Additional Phase 2 data read-outs expected in 4Q 2023, including topline from the IMPROVE-HCM...